« Back to Record
Citation APA

Cho, B., Hiltermann, J., Izumi, H., Brandão, M., Oliveira, S., Danchaivijitr, P., Felip, E., Ho, G., Leventakos, K., Li, Y., Sugawara, S., Voon, P.-J., Wauters, E., Yang, T.-Y., Yoshida, T., Chen, H., Achour, I., Colebrook, S., Liu, N., & Wang, Y. (2025). 1853MO Efficacy and safety of rilvegostomig, an anti-PD-1/TIGIT bispecific antibody, for checkpoint inhibitor (CPI)-naïve metastatic non-small cell lung cancer (mNSCLC): ARTEMIDE-01. Annals of oncology, 36, S997-S998. doi:10.1016/j.annonc.2025.08.2477


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/401693

Cho, B., Hiltermann, J., Izumi, H., Brandão, M., Oliveira, S., Danchaivijitr, P., Felip, E., Ho, G., Leventakos, K., Li, Y., Sugawara, S., Voon, P.-J., Wauters, E., Yang, T.-Y., Yoshida, T., Chen, H., Achour, I., Colebrook, S., Liu, N., & Wang, Y. (2025). 1853MO Efficacy and safety of rilvegostomig, an anti-PD-1/TIGIT bispecific antibody, for checkpoint inhibitor (CPI)-naïve metastatic non-small cell lung cancer (mNSCLC): ARTEMIDE-01. Annals of oncology, 36, S997-S998. doi:10.1016/j.annonc.2025.08.2477